Shares of Bellerophon Therapeutics Inc. (BLPH) are climbing over 534% in pre-market today, after the company announced that the U.S. Food and Drug Administration or FDA has granted emergency expanded access allowing its proprietary inhaled nitric oxide or iNO delivery system, INOpulse, to immediately be used for the treatment of COVID-19.
from RTT - Before the Bell https://ift.tt/3dgBRQD
via IFTTT
No comments:
Post a Comment